These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35225519)

  • 1. Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification.
    Bardoloi N; Sarkar S; Burgute PS; Deb AK; Dholkawala R; Aggarwal P; Gokhale T
    Indian J Ophthalmol; 2022 Mar; 70(3):807-812. PubMed ID: 35225519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between 0.1% Nepafenac and 1% Prednisolone Eye Drop in Postoperative Management Following Micro-incisional Cataract Surgery.
    Sarkar S; Bardoloi N; Deb AK
    Korean J Ophthalmol; 2021 Jun; 35(3):188-197. PubMed ID: 34120417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative analysis of topical corticosteroids and non-steroidal anti-inflammatory drugs to control inflammation and macular edema following uneventful phacoemulsification.
    Singhal D; Nanda A; Kanungo S; Sahoo K; Mohapatra S
    Indian J Ophthalmol; 2022 Feb; 70(2):425-433. PubMed ID: 35086209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study.
    Modi SS; Lehmann RP; Walters TR; Fong R; Christie WC; Roel L; Nethery D; Sager D; Tsorbatzoglou A; Philipson B; Traverso CE; Reiser H
    J Cataract Refract Surg; 2014 Feb; 40(2):203-11. PubMed ID: 24345529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification.
    Almeida DR; Khan Z; Xing L; Bakar SN; Rahim K; Urton T; El-Defrawy SR
    J Cataract Refract Surg; 2012 Sep; 38(9):1537-43. PubMed ID: 22795976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Effect of Diclofenac 0.1% and Nepafenac 0.1% on Aqueous Flare in Patients Undergoing Cataract Surgery: A Prospective Randomized Study.
    Cagini C; Pellegrino A; Cerquaglia A; Iaccheri B; Lupidi M; Fiore T
    Curr Eye Res; 2020 Sep; 45(9):1089-1093. PubMed ID: 32004437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of addition of nepafenac 0.1% to steroid eye drops in prevention of post-phaco macular edema in high-risk eyes.
    El Gharbawy SA; Darwish EA; Abu Eleinen KG; Osman MH
    Eur J Ophthalmol; 2019 Jul; 29(4):453-457. PubMed ID: 30203671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery.
    Zaczek A; Artzen D; Laurell CG; Stenevi U; Montan P
    J Cataract Refract Surg; 2014 Sep; 40(9):1498-505. PubMed ID: 25135542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery.
    Miyake K; Ota I; Miyake G; Numaga J
    J Cataract Refract Surg; 2011 Sep; 37(9):1581-8. PubMed ID: 21855758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.
    Singh RP; Lehmann R; Martel J; Jong K; Pollack A; Tsorbatzoglou A; Staurenghi G; Cervantes-Coste Cervantes G; Alpern L; Modi S; Svoboda L; Adewale A; Jaffe GJ
    Ophthalmology; 2017 Jun; 124(6):776-785. PubMed ID: 28268098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification.
    Tzelikis PF; Morato CS; Neves NT; Hida WT; Alves MR
    J Cataract Refract Surg; 2018 Apr; 44(4):440-446. PubMed ID: 29685777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac.
    Wolf EJ; Braunstein A; Shih C; Braunstein RE
    J Cataract Refract Surg; 2007 Sep; 33(9):1546-9. PubMed ID: 17720068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial.
    Colin J; Paquette B
    Clin Ther; 2006 Apr; 28(4):527-36. PubMed ID: 16750464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.
    Duong HV; Westfield KC; Chalkley TH
    J Cataract Refract Surg; 2007 Nov; 33(11):1925-9. PubMed ID: 17964399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.
    Sahu S; Ram J; Bansal R; Pandav SS; Gupta A
    J Cataract Refract Surg; 2015 Oct; 41(10):2043-8. PubMed ID: 26703278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of 0.1% Nepafenac versus 1% Prednisolone Acetate Eye Drops after Laser Peripheral Iridotomy: A Prospective, Randomized Trial.
    Gayam K; Ramulu PY; Rengaraj V; Srinivasan K
    Ophthalmol Glaucoma; 2020; 3(3):174-180. PubMed ID: 32672612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery.
    Lane SS; Modi SS; Lehmann RP; Holland EJ
    J Cataract Refract Surg; 2007 Jan; 33(1):53-8. PubMed ID: 17189793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
    Bucci FA; Waterbury LD
    Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.
    Maxwell WA; Reiser HJ; Stewart RH; Cavanagh HD; Walters TR; Sager DP; Meuse PA
    J Ocul Pharmacol Ther; 2008 Dec; 24(6):593-9. PubMed ID: 19040348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and toxicity of topically applied nepafenac 0.3% compared with generic ketorolac 0.5.
    Hovanesian J; Holland E
    J Cataract Refract Surg; 2019 Feb; 45(2):174-180. PubMed ID: 30527440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.